Cyberonics suffers depression trial setback
This article was originally published in Clinica
Cyberonics saw its shares plunge 56% last Tuesday after reporting that a pivotal trial of its vagus nerve stimulation (VNS) therapy for depression failed to show a significant difference between the treated and placebo patients. The company said that an application to market the treatment in the US as a treatment for the condition could be delayed by two to three years.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.